Trevi Therapeutics
TRVI
53 hedge funds and large institutions have $117M invested in Trevi Therapeutics in 2023 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 16 increasing their positions, 8 reducing their positions, and 5 closing their positions.
340% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 5
100% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 8
47% more funds holding
Funds holding: 36 → 53 (+17)
45% more capital invested
Capital invested by funds: $80.4M → $117M (+$36.3M)
8.9% more ownership
Funds ownership: 72.38% → 81.28% (+8.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.42M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.18M |
| 3 |
State Street
Boston,
Massachusetts
|
+$1.46M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.34M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$1.28M |
| 2 |
Renaissance Technologies
New York
|
-$373K |
| 3 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$166K |
| 4 |
IAM
Innovis Asset Management
Chicago,
Illinois
|
-$111K |
| 5 |
Millennium Management
New York
|
-$110K |
TRVI Hedge Fund Activity: Q2 2023 in Review
53 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q2 2023, worth a combined $117M — up 45% from $80.4M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new TRVI positions and 5 closed out — a net gain of 17 holders — while 16 added to existing stakes and 8 trimmed.
The largest buyer was BlackRock, adding an estimated $5.42M. The largest seller was Fairmount Funds Management, cutting an estimated $1.28M.
- 53 institutional investors held Trevi Therapeutics (TRVI) as of Q2 2023, up from 36 in Q1 2023.
- Funds reported $117M of Trevi Therapeutics stock for Q2 2023, up 45% quarter-over-quarter.
- 22 funds opened new Trevi Therapeutics positions in Q2 2023 and 5 closed out, a net change of +17 holders.
- The largest Trevi Therapeutics buyer in Q2 2023 was BlackRock, an estimated $5.42M added.
- The largest Trevi Therapeutics seller in Q2 2023 was Fairmount Funds Management, an estimated $1.28M sold.
Based on aggregated 13F filings for Q2 2023.